Pharmacological inhibition of voltage-gated Ca2+ channels for chronic pain relief

Current Neuropharmacology

Volumn 11, Issue 6, 2013, Pages 606-620

  Lee, Seungkyu ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Inhibition; L type Ca2+ channels; N type Ca2+ channels; Pain; T type Ca2+ channels; Targeting; Voltage gated Ca2+ channels; 2 subunit

Indexed keywords

AMPA RECEPTOR; ANALGESIC AGENT; BENZOTHIAZEPINE DERIVATIVE; BUTYLCAINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL R TYPE; CALCIUM CHANNEL T TYPE; CAPSAICIN; CYSTEINE; DIHYDROPYRIDINE; DILTIAZEM; GABAPENTIN; GLYCOSYLPHOSPHATIDYLINOSITOL; GRAMICIDIN; LIDOCAINE ETHOBROMIDE; NEUROTOXIN; NIFEDIPINE; OMEGA CONOTOXIN MVIIA; PHENYLALKYLAMINE; POTASSIUM CHANNEL; PREGABALIN; TRAZODONE; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; ZONISAMIDE;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CHRONIC PAIN; DOWN REGULATION; ELECTROPHYSIOLOGY; GENE SILENCING; GENE THERAPY; HIGH THROUGHPUT SCREENING; HUMAN; HYPERSENSITIVITY; MEDIATOR RELEASE; MEMBRANE DEPOLARIZATION; MEMBRANE STEADY POTENTIAL; NERVE EXCITABILITY; NEUROGENIC INFLAMMATION; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN RECEPTOR; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SCIATIC NERVE INJURY; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; UPREGULATION;

EID: 84899126267     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11311060005     Document Type: Article

References (173)

1. Woolf, C.J.; Ma, Q. Nociceptors--noxious stimulus detectors. Neuron, 2007, 55(3), 353-364.
2. Gover, T.D.; Kao, J.P.; Weinreich, D. Calcium signaling in single peripheral sensory nerve terminals. J. Neurosci., 2003, 23(12), 4793-4797.
3. Costigan, M.; Scholz, J.; Woolf, C.J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci., 2009, 32, 1-32.
4. Woolf, C.J. Overcoming obstacles to developing new analgesics. Nat. Med., 2010, 16(11), 1241-1247.
5. Smith, H.S. Current therapy in pain. Saunders/Elsevier: Philadelphia, 2009.
6. Catterall, W.A.; Few, A.P. Calcium channel regulation and presynaptic plasticity. Neuron, 2008, 59(6), 882-901.
7. Pexton, T.; Moeller-Bertram, T.; Schilling, J.M.; Wallace, M.S. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert. Opin. Investig. Drugs, 2011, 20(9), 1277-1284.
8. Catterall, W.A. Voltage-gated calcium channels. Cold Spring Harb Perspect. Biol., 2011, 3(8), a003947.
9. Catterall, W.A.; Perez-Reyes, E.; Snutch, T.P.; Striessnig, J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev., 2005, 57(4), 411-425.
10. Dolphin, A.C. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. Nat. Rev. Neurosci., 2012, 13(8), 542-555.
11. Dubel, S.J.; Starr, T.V.; Hell, J.; Ahlijanian, M.K.; Enyeart, J.J.; Catterall, W.A.; Snutch, T.P. Molecular cloning of the alpha-1 subunit of an omega-conotoxin-sensitive calcium channel. Proc. Natl. Acad. Sci. U. S. A., 1992, 89(11), 5058-5062.
12. Lacinova, L.; Klugbauer, N.; Hofmann, F. Absence of modulation of the expressed calcium channel alpha1G subunit by alpha2delta subunits. J. Physiol., 1999, 516 (Pt 3), 639-645.
13. 2+ channel beta subunit depletion in nodosus ganglion neurons. J. Neurosci., 1997, 17(17), 6621-6628.
14. Lipscombe, D.; Andrade, A.; Allen, S.E. Alternative splicing: Functional diversity among voltage-gated calcium channels and behavioral consequences. Biochim. Biophys. Acta, 2012.
15. Lipscombe, D.; Raingo, J. Alternative splicing matters: N-type calcium channels in nociceptors. Channels (Austin), 2007, 1(4), 225-227.
16. V2 calcium channels. Channels (Austin), 2010, 4(6), 483-489.
17. V2.2 channels modulates channel kinetics. J. Neurophysiol., 2004, 92(5), 2820-2830.
18. Bell, T.J.; Thaler, C.; Castiglioni, A.J.; Helton, T.D.; Lipscombe, D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron, 2004, 41(1), 127-138.
19. Raingo, J.; Castiglioni, A.J.; Lipscombe, D. Alternative splicing controls G protein-dependent inhibition of N-type calcium channels in nociceptors. Nat. Neurosci., 2007, 10(3), 285-292.
20. 2+ channels and spinal analgesia couple to alternative splicing. Nat. Neurosci., 2010, 13(10), 1249-1256.
21. Bean, B.P. The action potential in mammalian central neurons. Nat. Rev. Neurosci., 2007, 8(6), 451-465.
22. Helton, T.D.; Xu, W.; Lipscombe, D. Neuronal L-type calcium channels open quickly and are inhibited slowly. J. Neurosci., 2005, 25(44), 10247-10251.
23. v1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. J. Neurosci., 2010, 30(2), 491-504.
24. v2.3 channels are critical for oscillatory burst discharges in the reticular thalamus and absence epilepsy. Neuron, 2011, 70(1), 95-108.
25. Scroggs, R.S.; Fox, A.P. Calcium current variation between acutely isolated adult rat dorsal root ganglion neurons of different size. J Physiol., 1992, 445, 639-658.
26. Yusaf, S.P.; Goodman, J.; Pinnock, R.D.; Dixon, A.K.; Lee, K. Expression of voltage-gated calcium channel subunits in rat dorsal root ganglion neurons. Neurosci. Lett., 2001, 311(2), 137-141.
27. 2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J. Neurosci., 1998, 18(16), 6319-6330.
28. Ryu, P.D.; Randic, M. Low-and high-voltage-activated calcium currents in rat spinal dorsal horn neurons. J. Neurophysiol., 1990, 63(2), 273-285.
29. 2+ channels to nociceptive transmission in rat spinal lamina I neurons. Eur. J. Neurosci., 2004, 19(1), 103-111.
30. Yaksh, T.L. Calcium channels as therapeutic targets in neuropathic pain. J. Pain, 2006, 7(1 Suppl 1), S13-30.
31. Park, J.; Luo, Z.D. Calcium channel functions in pain processing. Channels (Austin), 2010, 4(6), 510-517.
32. (2+) channel alpha(1D) subunit in postnatal pancreatic beta cell generation. J. Clin. Invest., 2001, 108(7), 1015-1022.
33. Dobremez, E.; Bouali-Benazzouz, R.; Fossat, P.; Monteils, L.; Dulluc, J.; Nagy, F.; Landry, M. Distribution and regulation of L-type calcium channels in deep dorsal horn neurons after sciatic nerve injury in rats. Eur. J. Neurosci., 2005, 21(12), 3321-3333.
34. (V)1.3 immunoreactivity in the rat spinal cord and brain stem. Neuroscience, 2009, 159(1), 217-235.
35. Kim, D.S.; Yoon, C.H.; Lee, S.J.; Park, S.Y.; Yoo, H.J.; Cho, H.J. Changes in voltage-gated calcium channel alpha(1) gene expression in rat dorsal root ganglia following peripheral nerve injury. Brain Res. Mol. Brain Res., 2001, 96(1-2), 151-156.
36. (2)(+)- dependent regulation of Ca(2)(+) currents in rat primary afferent neurons: role of CaMKII and the effect of injury. J. Neurosci., 2012, 32(34), 11737-11749.
37. Fossat, P.; Dobremez, E.; Bouali-Benazzouz, R.; Favereaux, A.; Bertrand, S.S.; Kilk, K.; Leger, C.; Cazalets, J.R.; Langel, U.; Landry, M.; Nagy, F. Knockdown of L calcium channel subtypes: differential effects in neuropathic pain. J. Neurosci., 2010, 30(3), 1073-1085.
38. v1.2 calcium channel by microRNA miR-103: role in pain. EMBO J, 2011, 30(18), 3830-3841.
39. V1.3 in cat spinal cord: light and electron microscopic immunohistochemical study. J. Comp. Neurol., 2008, 507(1), 1109-1127.
40. 2+ channels. Neuroscience, 2003, 120(2), 435-442.
41. V2.1 voltage activated calcium channels and synaptic transmission in familial hemiplegic migraine pathogenesis. J. Physiol. Paris, 2012, 106(1-2), 12-22.
42. Poncer, J.C.; McKinney, R.A.; Gahwiler, B.H.; Thompson, S.M. Either N-or P-type calcium channels mediate GABA release at distinct hippocampal inhibitory synapses. Neuron, 1997, 18(3), 463-472.
43. Evans, A.R.; Nicol, G.D.; Vasko, M.R. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res., 1996, 712(2), 265-273.
44. Ohnami, S.; Tanabe, M.; Shinohara, S.; Takasu, K.; Kato, A.; Ono, H. Role of voltage-dependent calcium channel subtypes in spinal long-term potentiation of C-fiber-evoked field potentials. Pain, 2011, 152(3), 623-631.
45. Matthews, E.A.; Dickenson, A.H. Effects of spinally delivered N-and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain, 2001, 92(1-2), 235-246.
46. Chaplan, S.R.; Pogrel, J.W.; Yaksh, T.L. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J. Pharmacol. Exp. Ther., 1994, 269(3), 1117-1123.
47. Yamamoto, T.; Sakashita, Y. Differential effects of intrathecally administered N-and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. Brain Res., 1998, 794(2), 329-332.
48. 2+ channel mutant mouse, rolling mouse Nagoya. Neuroscience, 2009, 160(1), 165-173.
49. 2+ channels. Neuroscience, 2006, 142(3), 823-832.
50. (2+) channel mutant mice, leaner. FEBS Lett., 2001, 508(2), 181-186.
51. Westenbroek, R.E.; Hell, J.W.; Warner, C.; Dubel, S.J.; Snutch, T.P.; Catterall, W.A. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron, 1992, 9(6), 1099-1115.
52. Santicioli, P.; Del Bianco, E.; Tramontana, M.; Geppetti, P.; Maggi, C.A. Release of calcitonin gene-related peptide like-immunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin-sensitive calcium channels. Neurosci. Lett., 1992, 136(2), 161-164.
53. Gruner, W.; Silva, L.R. Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro. J. Neurosci., 1994, 14(5 Pt 1), 2800-2808.
54. Holz, G.G.t.; Dunlap, K.; Kream, R.M. Characterization of the electrically evoked release of substance P from dorsal root ganglion neurons: methods and dihydropyridine sensitivity. J. Neurosci., 1988, 8(2), 463-471.
55. Kerr, L.M.; Filloux, F.; Olivera, B.M.; Jackson, H.; Wamsley, J.K. Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain. Eur. J. Pharmacol., 1988, 146(1), 181-183.
56. Gohil, K.; Bell, J.R.; Ramachandran, J.; Miljanich, G.P. Neuro-anatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res., 1994, 653(1-2), 258-266.
57. Scroggs, R.S.; Fox, A.P. Multiple Ca2+ currents elicited by action potential waveforms in acutely isolated adult rat dorsal root ganglion neurons. J. Neurosci., 1992, 12(5), 1789-1801.
58. Lu, S.G.; Zhang, X.L.; Luo, Z.D.; Gold, M.S. Persistent inflammation alters the density and distribution of voltage-activated calcium channels in subpopulations of rat cutaneous DRG neurons. Pain, 2010, 151(3), 633-643.
59. 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res., 2002, 147(4), 456-463.
60. Luo, Z.D.; Chaplan, S.R.; Higuera, E.S.; Sorkin, L.S.; Stauderman, K.A.; Williams, M.E.; Yaksh, T.L. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J. Neurosci., 2001, 21(6), 1868-1875.
61. Rycroft, B.K.; Vikman, K.S.; Christie, M.J. Inflammation reduces the contribution of N-type calcium channels to primary afferent synaptic transmission onto NK1 receptor-positive lamina I neurons in the rat dorsal horn. J. Physiol., 2007, 580(Pt.3), 883-894.
62. Eroglu, C.; Allen, N.J.; Susman, M.W.; O'Rourke, N.A.; Park, C.Y.; Ozkan, E.; Chakraborty, C.; Mulinyawe, S.B.; Annis, D.S.; Huberman, A.D.; Green, E.M.; Lawler, J.; Dolmetsch, R.; Garcia, K.C.; Smith, S.J.; Luo, Z.D.; Rosenthal, A.; Mosher, D.F.; Barres, B.A. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell, 2009, 139(2), 380-392.
63. 2+ channel. EMBO J., 2001, 20(10), 2349-2356.
64. Kim, C.; Jun, K.; Lee, T.; Kim, S.S.; McEnery, M.W.; Chin, H.; Kim, H.L.; Park, J.M.; Kim, D.K.; Jung, S.J.; Kim, J.; Shin, H.S. Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol. Cell Neurosci., 2001, 18(2), 235-245.
65. (2+) channels. Neuroreport, 2001, 12(11), 2423-2427.
66. Sluka, K.A. Blockade of calcium channels can prevent the onset of secondary hyperalgesia and allodynia induced by intradermal injection of capsaicin in rats. Pain, 1997, 71(2), 157-164.
67. Sluka, K.A. Blockade of N-and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol. Exp. Ther., 1998, 287(1), 232-237.
68. McGivern, J.G. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr. Dis. Treat, 2007, 3(1), 69-85.
69. Scott, D.A.; Wright, C.E.; Angus, J.A. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur. J. Pharmacol., 2002, 451(3), 279-286.
70. Fang, Z.; Park, C.K.; Li, H.Y.; Kim, H.Y.; Park, S.H.; Jung, S.J.; Kim, J.S.; Monteil, A.; Oh, S.B.; Miller, R.J. Molecular basis of Ca(v)2.3 calcium channels in rat nociceptive neurons. J. Biol. Chem., 2007, 282(7), 4757-4764.
71. Fang, Z.; Hwang, J.H.; Kim, J.S.; Jung, S.J.; Oh, S.B. R-type Calcium Channel Isoform in Rat Dorsal Root Ganglion Neurons. Korean J. Physiol. Pharmacol., 2010, 14(1), 45-49.
72. v2.3 calcium channel antagonist SNX-482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain. Eur. J. Neurosci., 2007, 25(12), 3561-3569.
73. Murakami, M.; Nakagawasai, O.; Suzuki, T.; Mobarakeh, II; Sakurada, Y.; Murata, A.; Yamadera, F.; Miyoshi, I.; Yanai, K.; Tan-No, K.; Sasano, H.; Tadano, T.; Iijima, T. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel alpha 1 subunits in the dorsal horn of spinal cord in mice. Brain Res., 2004, 1024(1-2), 122-129.
74. Yang, L.; Stephens, G.J. Effects of neuropathy on high-voltage-activated Ca(2+) current in sensory neurones. Cell Calcium, 2009, 46(4), 248-256.
75. 2+ channel. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(11), 6132-6137.
76. (2+) channels on pain transmission. Neurosci. Res., 2002, 43(1), 1-7.
77. v3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J. Neurosci., 2012, 32(27), 9374-9382.
78. Weiss, N.; Zamponi, G.W. Control of low-threshold exocytosis by T-type calcium channels. Biochim. Biophys. Acta, 2012, 1828 (7), 1579-86.
79. Ikeda, H.; Heinke, B.; Ruscheweyh, R.; Sandkuhler, J. Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia. Science, 2003, 299(5610), 1237-1240.
80. Hogan, Q.H.; McCallum, J.B.; Sarantopoulos, C.; Aason, M.; Mynlieff, M.; Kwok, W.M.; Bosnjak, Z.J. Painful neuropathy decreases membrane calcium current in mammalian primary afferent neurons. Pain, 2000, 86(1-2), 43-53.
81. McCallum, J.B.; Kwok, W.M.; Mynlieff, M.; Bosnjak, Z.J.; Hogan, Q.H. Loss of T-type calcium current in sensory neurons of rats with neuropathic pain. Anesthesiology, 2003, 98(1), 209-216.
82. Jagodic, M.M.; Pathirathna, S.; Joksovic, P.M.; Lee, W.; Nelson, M.T.; Naik, A.K.; Su, P.; Jevtovic-Todorovic, V.; Todorovic, S.M. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J. Neurophysiol., 2008, 99(6), 3151-3156.
83. Wen, X.J.; Xu, S.Y.; Chen, Z.X.; Yang, C.X.; Liang, H.; Li, H. The roles of T-type calcium channel in the development of neuropathic pain following chronic compression of rat dorsal root ganglia. Pharmacology, 2010, 85(5), 295-300.
84. Shin, J.B.; Martinez-Salgado, C.; Heppenstall, P.A.; Lewin, G.R. A T-type calcium channel required for normal function of a mammalian mechanoreceptor. Nat. Neurosci., 2003, 6(7), 724-730.
85. Marger, F.; Gelot, A.; Alloui, A.; Matricon, J.; Ferrer, J.F.; Barrere, C.; Pizzoccaro, A.; Muller, E.; Nargeot, J.; Snutch, T.P.; Eschalier, A.; Bourinet, E.; Ardid, D. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc. Natl. Acad. Sci. U. S. A., 2011, 108(27), 11268-11273.
86. Latham, J.R.; Pathirathna, S.; Jagodic, M.M.; Choe, W.J.; Levin, M.E.; Nelson, M.T.; Lee, W.Y.; Krishnan, K.; Covey, D.F.; Todorovic, S.M.; Jevtovic-Todorovic, V. Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice. Diabetes, 2009, 58(11), 2656-2665.
87. v3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J, 2005, 24(2), 315-324.
88. v3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion. Acta Pharmacol. Sin., 2006, 27(12), 1547-1552.
89. (V)3.2 T-type channels. Genes Brain Behav., 2007, 6(5), 425-431.
90. 2+ channels. Science, 2003, 302(5642), 117-119.
91. v3.1 null mice. Mol. Cells, 2008, 25(2), 242-246.
92. Hoppa, M.B.; Lana, B.; Margas, W.; Dolphin, A.C.; Ryan, T.A. alpha2delta expression sets presynaptic calcium channel abundance and release probability. Nature, 2012, 486(7401), 122-125.
93. 2+ channel II: activation and inactivation by physiological patterns of activity. Neuropharmacology, 1998, 37(1), 67-81.
94. v2.2) calcium channels. J. Biol. Chem., 2004, 279(33), 34705-34714.
95. Bauer, C.S.; Rahman, W.; Tran-van-Minh, A.; Lujan, R.; Dickenson, A.H.; Dolphin, A.C. The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo. Biochem. Soc. Trans., 2010, 38(2), 525-528.
96. Newton, R.A.; Bingham, S.; Case, P.C.; Sanger, G.J.; Lawson, S.N. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res. Mol. Brain Res., 2001, 95(1-2), 1-8.
97. Neely, G.G.; Hess, A.; Costigan, M.; Keene, A.C.; Goulas, S.; Langeslag, M.; Griffin, R.S.; Belfer, I.; Dai, F.; Smith, S.B.; Diatchenko, L.; Gupta, V.; Xia, C.P.; Amann, S.; Kreitz, S.; Heindl-Erdmann, C.; Wolz, S.; Ly, C.V.; Arora, S.; Sarangi, R.; Dan, D.; Novatchkova, M.; Rosenzweig, M.; Gibson, D.G.; Truong, D.; Schramek, D.; Zoranovic, T.; Cronin, S.J.; Angjeli, B.; Brune, K.; Dietzl, G.; Maixner, W.; Meixner, A.; Thomas, W.; Pospisilik, J.A.; Alenius, M.; Kress, M.; Subramaniam, S.; Garrity, P.A.; Bellen, H.J.; Woolf, C.J.; Penninger, J.M. A genome-wide Drosophila screen for heat nociception identifies alpha2delta3 as an evolutionarily conserved pain gene. Cell, 2010, 143(4), 628-638.
98. Hendrich, J.; Van Minh, A.T.; Heblich, F.; Nieto-Rostro, M.; Watschinger, K.; Striessnig, J.; Wratten, J.; Davies, A.; Dolphin, A.C. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(9), 3628-3633.
99. Sutton, K.G.; Martin, D.J.; Pinnock, R.D.; Lee, K.; Scott, R.H. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br. J. Pharmacol., 2002, 135(1), 257-265.
100. Stefani, A.; Spadoni, F.; Bernardi, G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology, 1998, 37(1), 83-91.
101. (2)(+) channel complex. Nat. Med., 2011, 17(7), 822-829.
102. Snutch, T.P.; Sutton, K.G.; Zamponi, G.W. Voltage-dependent calcium channels--beyond dihydropyridine antagonists. Curr. Opin. Pharmacol., 2001, 1(1), 11-16.
103. Fleckenstein, A. History of calcium antagonists. Circ. Res., 1983, 52(2 Pt 2), I3-16.
104. Schuster, A.; Lacinova, L.; Klugbauer, N.; Ito, H.; Birnbaumer, L.; Hofmann, F. The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. EMBO J, 1996, 15(10), 2365-2370.
105. 2+ channel agonists. J. Biol. Chem., 2000, 275(52), 41504-41511.
106. (2+) channels. Mol. Pharmacol., 2000, 58(6), 1264-1270.
107. Kass, R.S.; Arena, J.P.; Chin, S. Block of L-type calcium channels by charged dihydropyridines. Sensitivity to side of application and calcium. J. Gen. Physiol., 1991, 98(1), 63-75.
108. Voltage-gated ion channels as drug targets. Wiley-VCH: Weinheim, 2006.
109. Bean, B.P. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc. Natl. Acad. Sci. U. S. A., 1984, 81(20), 6388-6392.
110. Sasaki, T.; Feng, Z.P.; Scott, R.; Grigoriev, N.; Syed, N.I.; Fainzilber, M.; Sato, K. Synthesis, bioactivity, and cloning of the L-type calcium channel blocker omega-conotoxin TxVII. Biochemistry, 1999, 38(39), 12876-12884.
111. Malmberg, A.B.; Yaksh, T.L. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N-and P-type channels inhibits formalin-induced nociception. J. Neurosci., 1994, 14(8), 4882-4890.
112. Todorovic, S.M.; Pathirathna, S.; Meyenburg, A.; Jevtovic-Todorovic, V. Mechanical and thermal anti-nociception in rats after systemic administration of verapamil. Neurosci. Lett., 2004, 360(1-2), 57-60.
113. Weizman, R.; Getslev, V.; Pankova, I.A.; Schrieber, S.; Pick, C.G. Pharmacological interaction of the calcium channel blockers verapamil and flunarizine with the opioid system. Brain Res., 1999, 818(2), 187-195.
114. Ellinor, P.T.; Zhang, J.F.; Horne, W.A.; Tsien, R.W. Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin. Nature, 1994, 372(6503), 272-275.
115. Feng, Z.P.; Doering, C.J.; Winkfein, R.J.; Beedle, A.M.; Spafford, J.D.; Zamponi, G.W. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J. Biol. Chem., 2003, 278(22), 20171-20178.
116. Penn, R.D.; Paice, J.A. Adverse effects associated with the intrathecal administration of ziconotide. Pain, 2000, 85(1-2), 291-296.
117. Kolosov, A.; Aurini, L.; Williams, E.D.; Cooke, I.; Goodchild, C.S. Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Med., 2011, 12(6), 923-941.
118. Chen, J.Q.; Zhang, Y.Q.; Dai, J.; Luo, Z.M.; Liang, S.P. Antinociceptive effects of intrathecally administered huwentoxin-I, a selective N-type calcium channel blocker, in the formalin test in conscious rats. Toxicon, 2005, 45(1), 15-20.
119. de Souza, A.H.; Lima, M.C.; Drewes, C.C.; da Silva, J.F.; Torres, K.C.; Pereira, E.M.; de Castro Junior, C.J.; Vieira, L.B.; Cordeiro, M.N.; Richardson, M.; Gomez, R.S.; Romano-Silva, M.A.; Ferreira, J.; Gomez, M.V. Antiallodynic effect and side effects of Phalpha1beta, a neurotoxin from the spider Phoneutria nigriventer: comparison with omega-conotoxin MVIIA and morphine. Toxicon, 2011, 58(8), 626-633.
120. Yamamoto, T.; Takahara, A. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr. Top Med. Chem., 2009, 9(4), 377-395.
121. Zamponi, G.W.; Feng, Z.P.; Zhang, L.; Pajouhesh, H.; Ding, Y.; Belardetti, F.; Dolphin, D.; Mitscher, L.A.; Snutch, T.P. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg. Med. Chem. Lett., 2009, 19(22), 6467-6472.
122. Pajouhesh, H.; Feng, Z.P.; Zhang, L.; Jiang, X.; Hendricson, A.; Dong, H.; Tringham, E.; Ding, Y.; Vanderah, T.W.; Porreca, F.; Belardetti, F.; Zamponi, G.W.; Mitscher, L.A.; Snutch, T.P. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(12), 4153-4158.
123. v2.2 channel inhibitors for the treatment of chronic pain. J. Med. Chem., 2012, 55(22), 9847-9855.
124. Abbadie, C.; McManus, O.B.; Sun, S.Y.; Bugianesi, R.M.; Dai, G.; Haedo, R.J.; Herrington, J.B.; Kaczorowski, G.J.; Smith, M.M.; Swensen, A.M.; Warren, V.A.; Williams, B.; Arneric, S.P.; Eduljee, C.; Snutch, T.P.; Tringham, E.W.; Jochnowitz, N.; Liang, A.; Euan MacIntyre, D.; McGowan, E.; Mistry, S.; White, V.V.; Hoyt, S.B.; London, C.; Lyons, K.A.; Bunting, P.B.; Volksdorf, S.; Duffy, J.L. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J. Pharmacol. Exp. Ther., 2010, 334(2), 545-555.
125. (V)2 calcium channels. Mol. Pharmacol., 2012, 81(3), 488-497.
126. Seko, T.; Kato, M.; Kohno, H.; Ono, S.; Hashimura, K.; Takenobu, Y.; Takimizu, H.; Nakai, K.; Maegawa, H.; Katsube, N.; Toda, M. L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models. Bioorg. Med. Chem. Lett., 2002, 12(17), 2267-2269.
127. Seko, T.; Kato, M.; Kohno, H.; Ono, S.; Hashimura, K.; Takimizu, H.; Nakai, K.; Maegawa, H.; Katsube, N.; Toda, M. Structure-activity study of L-amino acid-based N-type calcium channel blockers. Bioorg. Med. Chem., 2003, 11(8), 1901-1913.
128. Pitt, B. Diversity of calcium antagonists. Clin. Ther., 1997, 19 Suppl A, 3-17.
129. Bakx, A.L.; van der Wall, E.E.; Braun, S.; Emanuelsson, H.; Bruschke, A.V.; Kobrin, I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group. Am. Heart J., 1995, 130(4), 748-757.
130. Veronese, M.L.; Gillen, L.P.; Dorval, E.P.; Hauck, W.W.; Waldman, S.A.; Greenberg, H.E. Effect of mibefradil on CYP3A4 in vivo. J. Clin. Pharmacol., 2003, 43(10), 1091-1100.
131. Todorovic, S.M.; Meyenburg, A.; Jevtovic-Todorovic, V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res., 2002, 951(2), 336-340.
132. Dogrul, A.; Gardell, L.R.; Ossipov, M.H.; Tulunay, F.C.; Lai, J.; Porreca, F. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain, 2003, 105(1-2), 159-168.
133. Dogrul, A.; Zagli, U.; Tulunay, F.C. The role of T-type calcium channels in morphine analgesia, development of antinociceptive tolerance and dependence to morphine, and morphine abstinence syndrome. Life Sci., 2002, 71(6), 725-734.
134. (2+) channel blocker, on dorsal horn neuronal responses in rats. Eur. J. Pharmacol., 2001, 415(2-3), 141-149.
135. Flatters, S.J.; Bennett, G.J. Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy. Pain, 2004, 109(1-2), 150-161.
136. Reger, T.S.; Yang, Z.Q.; Schlegel, K.A.; Shu, Y.; Mattern, C.; Cube, R.; Rittle, K.E.; McGaughey, G.B.; Hartman, G.D.; Tang, C.; Ballard, J.; Kuo, Y.; Prueksaritanont, T.; Nuss, C.E.; Doran, S.M.; Fox, S.V.; Garson, S.L.; Li, Y.; Kraus, R.L.; Uebele, V.N.; Renger, J.J.; Barrow, J.C. Pyridyl amides as potent inhibitors of T-type calcium channels. Bioorg. Med. Chem. Lett., 2011, 21(6), 1692-1696.
137. Francois, A.; Kerckhove, N.; Meleine, M.; Alloui, A.; Barrere, C.; Gelot, A.; Uebele, V.N.; Renger, J.J.; Eschalier, A.; Ardid, D.; Bourinet, E. State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. Pain, 2013, 154(2), 283-293.
138. Kraus, R.L.; Li, Y.; Gregan, Y.; Gotter, A.L.; Uebele, V.N.; Fox, S.V.; Doran, S.M.; Barrow, J.C.; Yang, Z.Q.; Reger, T.S.; Koblan, K.S.; Renger, J.J. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J. Pharmacol. Exp. Ther., 2010, 335(2), 409-417.
139. Uebele, V.N.; Nuss, C.E.; Fox, S.V.; Garson, S.L.; Cristescu, R.; Doran, S.M.; Kraus, R.L.; Santarelli, V.P.; Li, Y.; Barrow, J.C.; Yang, Z.Q.; Schlegel, K.A.; Rittle, K.E.; Reger, T.S.; Bednar, R.A.; Lemaire, W.; Mullen, F.A.; Ballard, J.E.; Tang, C.; Dai, G.; McManus, O.B.; Koblan, K.S.; Renger, J.J. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem. Biophys., 2009, 55(2), 81-93.
140. 2+ channel antagonist. J. Med. Chem., 2008, 51(13), 3692-3695.
141. Yang, Z.Q.; Barrow, J.C.; Shipe, W.D.; Schlegel, K.A.; Shu, Y.; Yang, F.V.; Lindsley, C.W.; Rittle, K.E.; Bock, M.G.; Hartman, G.D.; Uebele, V.N.; Nuss, C.E.; Fox, S.V.; Kraus, R.L.; Doran, S.M.; Connolly, T.M.; Tang, C.; Ballard, J.E.; Kuo, Y.; Adarayan, E.D.; Prueksaritanont, T.; Zrada, M.M.; Marino, M.J.; Graufelds, V.K.; DiLella, A.G.; Reynolds, I.J.; Vargas, H.M.; Bunting, P.B.; Woltmann, R.F.; Magee, M.M.; Koblan, K.S.; Renger, J.J. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J. Med. Chem., 2008, 51(20), 6471-6477.
142. Bladen, C.; Zamponi, G.W. Common mechanisms of drug interactions with sodium and T-type calcium channels. Mol. Pharmacol., 2012, 82(3), 481-487.
143. Leppik, I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure, 2004, 13 Suppl 1, S5-9; discussion S10.
144. Takahashi, Y.; Hashimoto, K.; Tsuji, S. Successful use of zonisamide for central poststroke pain. J. Pain, 2004, 5(3), 192-194.
145. Matar, N.; Jin, W.; Wrubel, H.; Hescheler, J.; Schneider, T.; Weiergraber, M. Zonisamide block of cloned human T-type voltage-gated calcium channels. Epilepsy Res., 2009, 83(2-3), 224-234.
146. Beekwilder, J.P.; van Kempen, G.T.; van den Berg, R.J.; Ypey, D.L. The local anesthetic butamben inhibits and accelerates low-voltage activated T-type currents in small sensory neurons. Anesth. Analg., 2006, 102(1), 141-145.
147. Barton, M.E.; Eberle, E.L.; Shannon, H.E. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur. J. Pharmacol., 2005, 521(1-3), 79-85.
148. Zhang, Y.F.; Gibbs, J.W., 3rd; Coulter, D.A. Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: ethosuximide, trimethadione, and dimethadione. Epilepsy Res., 1996, 23(1), 15-36.
149. Barbara, G.; Alloui, A.; Nargeot, J.; Lory, P.; Eschalier, A.; Bourinet, E.; Chemin, J. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J. Neurosci., 2009, 29(42), 13106-13114.
150. 2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. Mol. Pharmacol., 2004, 66(5), 1223-1235.
151. Pathirathna, S.; Brimelow, B.C.; Jagodic, M.M.; Krishnan, K.; Jiang, X.; Zorumski, C.F.; Mennerick, S.; Covey, D.F.; Todorovic, S.M.; Jevtovic-Todorovic, V. New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5alpha-reduced neuroactive steroids. Pain, 2005, 114(3), 429-443.
152. Chuang, R.S.; Jaffe, H.; Cribbs, L.; Perez-Reyes, E.; Swartz, K.J. Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat. Neurosci., 1998, 1(8), 668-674.
153. Sidach, S.S.; Mintz, I.M. Kurtoxin, a gating modifier of neuronal high-and low-threshold ca channels. J. Neurosci., 2002, 22(6), 2023-2034.
154. v3.2. J. Pharmacol. Sci., 2010, 112(4), 452-458.
155. (2+) channels. Biochemistry, 2012, 51(9), 1862-1873.
156. Binshtok, A.M.; Bean, B.P.; Woolf, C.J. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature, 2007, 449(7162), 607-610.
157. Brenneis, C.; Kistner, K.; Puopolo, M.; Segal, D.; Roberson, D.; Sisignano, M.; Labocha, S.; Ferreiros, N.; Strominger, A.; Cobos, E.J.; Ghasemlou, N.; Geisslinger, G.; Reeh, P.W.; Bean, B.P.; Woolf, C.J. Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J. Neurosci., 2013, 33(1), 315-326.
158. Puopolo, M.; Binshtok, A.M.; Yao, G.L.; Oh, S.B.; Woolf, C.J.; Bean, B.P. Permeation and block of TRPV1 channels by the cationic lidocaine derivative QX-314. J. Neurophysiol., 2013, 109(7),1704-12.
159. Kwan, Y.W.; Bangalore, R.; Lakitsh, M.; Glossmann, H.; Kass, R.S. Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site. J. Mol. Cell Cardiol., 1995, 27(1), 253-262.
160. 2+ channel in vascular smooth muscle cells: comparison with permanently charged derivative, D 890. Am. J. Physiol., 1989, 257(4 Pt 1), C689-695.
161. Snutch, T.P. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx, 2005, 2(4), 662-670.
162. Grienberger, C.; Konnerth, A. Imaging calcium in neurons. Neuron, 2012, 73(5), 862-885.
163. Sogaard, R.; Ljungstrom, T.; Pedersen, K.A.; Olesen, S.P.; Jensen, B.S. KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am. J. Physiol. Cell Physiol., 2001, 280(4), C859-866.
164. Hermann, D.; Mezler, M.; Swensen, A.M.; Bruehl, C.; Obergru Berger, A.; Wicke, K.; Schoemaker, H.; Gross, G.; Draguhn, A.; Nimmrich, V. Establishment of a secondary screening assay for p/q-type calcium channel blockers. Comb. Chem. High Throughput Screen, 2013, 16(3), 233-243.
165. 2+ channels and comparison with patch-clamp studies. Comb. Chem. High Throughput Screen, 2009, 12(3), 296-302.
166. Xie, X.; Van Deusen, A.L.; Vitko, I.; Babu, D.A.; Davies, L.A.; Huynh, N.; Cheng, H.; Yang, N.; Barrett, P.Q.; Perez-Reyes, E. Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev. Technol., 2007, 5(2), 191-203.
167. Belardetti, F.; Tringham, E.; Eduljee, C.; Jiang, X.; Dong, H.; Hendricson, A.; Shimizu, Y.; Janke, D.L.; Parker, D.; Mezeyova, J.; Khawaja, A.; Pajouhesh, H.; Fraser, R.A.; Arneric, S.P.; Snutch, T.P. A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers. Assay Drug Dev. Technol., 2009, 7(3), 266-280.
168. Miwa, J.M.; Ibanez-Tallon, I.; Crabtree, G.W.; Sanchez, R.; Sali, A.; Role, L.W.; Heintz, N. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron, 1999, 23(1), 105-114.
169. von Engelhardt, J.; Mack, V.; Sprengel, R.; Kavenstock, N.; Li, K.W.; Stern-Bach, Y.; Smit, A.B.; Seeburg, P.H.; Monyer, H. CKAMP44: a brain-specific protein attenuating short-term synaptic plasticity in the dentate gyrus. Science, 2010, 327(5972), 1518-1522.
170. Ibanez-Tallon, I.; Wen, H.; Miwa, J.M.; Xing, J.; Tekinay, A.B.; Ono, F.; Brehm, P.; Heintz, N. Tethering naturally occurring peptide toxins for cell-autonomous modulation of ion channels and receptors in vivo. Neuron, 2004, 43(3), 305-311.
171. Auer, S.; Sturzebecher, A.S.; Juttner, R.; Santos-Torres, J.; Hanack, C.; Frahm, S.; Liehl, B.; Ibanez-Tallon, I. Silencing neurotransmission with membrane-tethered toxins. Nat. Methods, 2010, 7(3), 229-236.
172. Anliker, B.; Abel, T.; Kneissl, S.; Hlavaty, J.; Caputi, A.; Brynza, J.; Schneider, I.C.; Munch, R.C.; Petznek, H.; Kontermann, R.E.; Koehl, U.; Johnston, I.C.; Keinanen, K.; Muller, U.C.; Hohenadl, C.; Monyer, H.; Cichutek, K.; Buchholz, C.J. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat. Methods, 2010, 7(11), 929-935.
173. Moran, N. First gene therapy nears landmark European market authorization. Nat. Biotechnol., 2012, 30(9), 807-809.